Logo image of FDMT

4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Fundamental Analysis

USA - NASDAQ:FDMT - US35104E1001 - Common Stock

6.845 USD
+0.25 (+3.71%)
Last: 9/22/2025, 11:19:46 AM
Fundamental Rating

3

Overall FDMT gets a fundamental rating of 3 out of 10. We evaluated FDMT against 538 industry peers in the Biotechnology industry. While FDMT has a great health rating, there are worries on its profitability. FDMT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FDMT had negative earnings in the past year.
In the past year FDMT has reported a negative cash flow from operations.
In the past 5 years FDMT always reported negative net income.
FDMT had a negative operating cash flow in each of the past 5 years.
FDMT Yearly Net Income VS EBIT VS OCF VS FCFFDMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

FDMT has a Return On Assets (-41.41%) which is in line with its industry peers.
The Return On Equity of FDMT (-46.60%) is better than 67.47% of its industry peers.
Industry RankSector Rank
ROA -41.41%
ROE -46.6%
ROIC N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
FDMT Yearly ROA, ROE, ROICFDMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FDMT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FDMT Yearly Profit, Operating, Gross MarginsFDMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

7

2. Health

2.1 Basic Checks

FDMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
FDMT has more shares outstanding than it did 1 year ago.
FDMT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for FDMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FDMT Yearly Shares OutstandingFDMT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
FDMT Yearly Total Debt VS Total AssetsFDMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

FDMT has an Altman-Z score of 0.65. This is a bad value and indicates that FDMT is not financially healthy and even has some risk of bankruptcy.
FDMT's Altman-Z score of 0.65 is fine compared to the rest of the industry. FDMT outperforms 62.27% of its industry peers.
FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.65
ROIC/WACCN/A
WACC9.84%
FDMT Yearly LT Debt VS Equity VS FCFFDMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 8.75 indicates that FDMT has no problem at all paying its short term obligations.
FDMT has a Current ratio of 8.75. This is in the better half of the industry: FDMT outperforms 76.39% of its industry peers.
A Quick Ratio of 8.75 indicates that FDMT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.75, FDMT is in the better half of the industry, outperforming 76.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.75
Quick Ratio 8.75
FDMT Yearly Current Assets VS Current LiabilitesFDMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

FDMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.82%.
The Revenue for FDMT has decreased by -99.92% in the past year. This is quite bad
Measured over the past years, FDMT shows a very negative growth in Revenue. The Revenue has been decreasing by -64.95% on average per year.
EPS 1Y (TTM)-54.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
Revenue 1Y (TTM)-99.92%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%200%

3.2 Future

The Earnings Per Share is expected to decrease by -7.85% on average over the next years.
The Revenue is expected to grow by 130.91% on average over the next years. This is a very strong growth
EPS Next Y-24.97%
EPS Next 2Y-13.7%
EPS Next 3Y-10.64%
EPS Next 5Y-7.85%
Revenue Next Year105.44%
Revenue Next 2Y39.16%
Revenue Next 3Y40.14%
Revenue Next 5Y130.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FDMT Yearly Revenue VS EstimatesFDMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
FDMT Yearly EPS VS EstimatesFDMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FDMT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FDMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDMT Price Earnings VS Forward Price EarningsFDMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FDMT Per share dataFDMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as FDMT's earnings are expected to decrease with -10.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.7%
EPS Next 3Y-10.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FDMT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4D MOLECULAR THERAPEUTICS IN

NASDAQ:FDMT (9/22/2025, 11:19:46 AM)

6.845

+0.25 (+3.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-11 2025-11-11/amc
Inst Owners96.57%
Inst Owner Change-6.75%
Ins Owners3.88%
Ins Owner Change0%
Market Cap319.66M
Analysts80
Price Target29.35 (328.78%)
Short Float %9.56%
Short Ratio3.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.75%
Min EPS beat(2)-9.71%
Max EPS beat(2)2.21%
EPS beat(4)1
Avg EPS beat(4)-6.46%
Min EPS beat(4)-10.47%
Max EPS beat(4)2.21%
EPS beat(8)5
Avg EPS beat(8)7.58%
EPS beat(12)8
Avg EPS beat(12)6.75%
EPS beat(16)11
Avg EPS beat(16)5.29%
Revenue beat(2)0
Avg Revenue beat(2)-96.24%
Min Revenue beat(2)-96.41%
Max Revenue beat(2)-96.07%
Revenue beat(4)0
Avg Revenue beat(4)-97.97%
Min Revenue beat(4)-99.94%
Max Revenue beat(4)-96.07%
Revenue beat(8)2
Avg Revenue beat(8)55.45%
Revenue beat(12)2
Avg Revenue beat(12)16.36%
Revenue beat(16)4
Avg Revenue beat(16)46.83%
PT rev (1m)-2.63%
PT rev (3m)-2.63%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)-3.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)-22.94%
Revenue NQ rev (3m)-22.91%
Revenue NY rev (1m)-13.46%
Revenue NY rev (3m)-34.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9686.71
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-3.85
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.56
OCFYN/A
SpS0
BVpS9.01
TBVpS9.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.41%
ROE -46.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.91%
Cap/Sales 10375.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.75
Quick Ratio 8.75
Altman-Z 0.65
F-Score2
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)195.17%
Cap/Depr(5y)250.86%
Cap/Sales(3y)3538.16%
Cap/Sales(5y)2134.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
EPS Next Y-24.97%
EPS Next 2Y-13.7%
EPS Next 3Y-10.64%
EPS Next 5Y-7.85%
Revenue 1Y (TTM)-99.92%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%200%
Revenue Next Year105.44%
Revenue Next 2Y39.16%
Revenue Next 3Y40.14%
Revenue Next 5Y130.91%
EBIT growth 1Y-6.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.72%
EBIT Next 3Y-16.47%
EBIT Next 5YN/A
FCF growth 1Y-73.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.51%
OCF growth 3YN/A
OCF growth 5YN/A